Sandbox:Hyperlipoproteinemia type5: Difference between revisions
| Line 34: | Line 34: | ||
For patients in whom lipid-altering drug therapy is indicated, statin treatment is the primary pharmacologic modality for reducing ASCVD risk. | For patients in whom lipid-altering drug therapy is indicated, statin treatment is the primary pharmacologic modality for reducing ASCVD risk. | ||
===Medical Therapy=== | ===Medical Therapy=== | ||
When the triglyceride concentration is very high (≥500 mg/dL, and especially if ≥1000 mg/dL), the primary goal of therapy is to reduce the triglyceride level to , ≥500 mg/dL for the intent of reducing the risk of pancreatitis. | When the triglyceride concentration is very high (≥500 mg/dL, and especially if ≥1000 mg/dL), the primary goal of therapy is to reduce the triglyceride level to , ≥500 mg/dL for the intent of reducing the risk of pancreatitis. | ||
When triglycerides are between 200 and 499mg/dL, the primary targets of lipid therapy are non–HDL-C and LDL-C for the purpose of reducing [[ASCVD]] risk. | When triglycerides are between 200 and 499mg/dL, the primary targets of lipid therapy are non–HDL-C and LDL-C for the purpose of reducing [[ASCVD]] risk. | ||
HDL-C is not a specific target of therapy; however, HDL-C levels may be increased as a consequence of favorable lifestyle intervention and certain lipid-altering drug therapies that reduces the risk of [[ASCVD]] | HDL-C is not a specific target of therapy; however, HDL-C levels may be increased as a consequence of favorable lifestyle intervention and certain lipid-altering drug therapies that reduces the risk of [[ASCVD]] | ||
Revision as of 01:57, 28 November 2016
|
Breast Cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sandbox:Hyperlipoproteinemia type5 On the Web |
|
American Roentgen Ray Society Images of Sandbox:Hyperlipoproteinemia type5 |
|
Risk calculators and risk factors for Sandbox:Hyperlipoproteinemia type5 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Person 1, Person 2, Your Name
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Any Disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
A reduced HDL-C level is associate with ASCVD
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies This summary should not be interpreted as rules or directives with regard to the most appropriate care of any single patient with dyslipidemia, because no set of recommendations or guidelines can have 100% applicability to an individual patient. Thus, evaluation and treatment decisions should be based on patient-centered, individual circumstances. As such, this document should be used in conjunction with, and not a replacement for the preferences of patients with dyslipidemia and the judgment of their treating clinicians.[1] Lifestyle therapies, such as appropriate nutrition and physical activity, are important elements of ASCVD risk reduction, with or without lipid-altering drug therapy. For patients in whom lipid-altering drug therapy is indicated, statin treatment is the primary pharmacologic modality for reducing ASCVD risk.
Medical Therapy
When the triglyceride concentration is very high (≥500 mg/dL, and especially if ≥1000 mg/dL), the primary goal of therapy is to reduce the triglyceride level to , ≥500 mg/dL for the intent of reducing the risk of pancreatitis. When triglycerides are between 200 and 499mg/dL, the primary targets of lipid therapy are non–HDL-C and LDL-C for the purpose of reducing ASCVD risk. HDL-C is not a specific target of therapy; however, HDL-C levels may be increased as a consequence of favorable lifestyle intervention and certain lipid-altering drug therapies that reduces the risk of ASCVD
Case Studies
References
- ↑ Bays HE, Jones PH, Orringer CE, Brown WV, Jacobson TA (2016). "National Lipid Association Annual Summary of Clinical Lipidology 2016". J Clin Lipidol. 10 (1 Suppl): S1–43. doi:10.1016/j.jacl.2015.08.002. PMID 26891998.